Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
Related Questions
Given that cardiovascular disease is the top cause of morbidity/mortality in patients with MASLD, do you perform any additional screening and/or testing for these patients to minimize this impact?
In patients with MASLD/MASH, do you perform any cardiac testing to create a patient's risk profile, given that cardiac complications are the top cause of morbidity and mortality in this patient population (especially those with advanced fibrosis)?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?
What are your biggest takeaways from the MASH-TAG 2025 conference?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
In what scenario would you opt to perform an MRI-PDFF in a patient with MASLD/MASH or in whom you suspect has this? Why would you opt for this over a Fibroscan or other NILDA?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
In patients with Met-ALD, how do you approach their treatment plan?
